Navigation Links
OncoGenex Pharmaceuticals Announces OGX-011 Treatment Provides Survival Benefit in Randomized Phase 2 Trial in Advanced Metastatic Prostate Cancer
Date:5/30/2009

Group (NCIC CTG) based at Queen's University in Kingston, Ontario. The trial was further supported by an unrestricted grant from Sanofi-Aventis.

Webcast and Conference Call Today

OncoGenex will hold a live webcast and conference call of presentations made at a Company hosted reception during the 2009 American Society of Clinical Oncology Annual Meeting (ASCO) today, May 30, 2009. The webcast will begin at 7:10 p.m. EDT.

During the reception, OncoGenex management and guest speakers will provide a comprehensive review of the final results of the randomized Phase 2 trial presented at the ASCO Annual Meeting, as well as discuss the treatment landscape and the relevance of clinical trial endpoints for prostate cancer.

To access the webcast, log on to the Investor Relations page of the OncoGenex Web site at www.oncogenex.com. Alternatively, you may access the live conference call by dialing 877-627-6544 (U.S. & Canada) or 719-325-4857 (International). A webcast replay will be available approximately two hours after the call and will be archived at www.oncogenex.com.

About OGX-011

OGX-011 is designed to inhibit the production of clusterin, a protein that is associated with cancer treatment resistance and is currently being evaluated in Phase 2 clinical trials in prostate, lung and breast cancer. At the 2009 American Urological Association Annual Meeting, OncoGenex reported Phase 2 data with OGX-011 in combination with second-line treatment of metastatic castrate resistant prostate cancer showing better than expected survival results, reductions in levels of clusterin, durable reductions in pain, and a decline in PSA, a protein that is often elevated in patients with prostate cancer.

Based on clinical results to date, OncoGenex intends to conduct Phase 3 registration trials
'/>"/>

SOURCE OncoGenex Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. OncoGenex Pharmaceuticals Announces OGX-427 Treatment Demonstrates Safety, Evidence of Declines in Circulating Tumor Cells and Reductions in Tumor Markers in a Phase 1 Cancer Trial
2. OncoGenex Pharmaceuticals to Webcast ASCO Reception on May 30, 2009
3. OncoGenex Pharmaceuticals Announces Release of Two ASCO Abstracts: Impact of OGX-011 on Survival in Randomized Phase 2 Trial and Phase 1 Safety Data for OGX-427
4. OncoGenex Pharmaceuticals Clinical Programs to be Featured in Oral Presentations at the American Society of Clinical Oncology Annual Meeting
5. OncoGenex Reports First Quarter Financial Results
6. OncoGenex Pharmaceuticals to Release First Quarter Financial Results
7. OncoGenex Receives Confirmation from FDA on the Design of a Second Phase 3 Trial Evaluating OGX-011 for the Treatment of Advanced Prostate Cancer
8. OncoGenex Pharmaceuticals Named Life Sciences Company of the Year by LifeSciences British Columbia
9. OncoGenex Reports Financial Results for Fourth Quarter and Fiscal Year 2008 and Provides Outlook for 2009
10. OncoGenex Pharmaceuticals to Webcast Financial Results for Fourth Quarter and Fiscal Year 2008 and Provide Outlook for 2009
11. OncoGenex Provides Update on Two-Year Survival Data from Ongoing Phase 1/2 Clinical Trial of OGX-011 in Non-Small Cell Lung Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... are based on electrons, but one of the most ... i.e. circuits based on light (photons) instead of electrons. ... a stream of single photons and control their direction. ... attempts to achieve this control, but now scientists at ... steady stream of photons emitted one at a time ...
(Date:8/29/2014)... , Aug. 29, 2014 /PRNewswire/ - iCo ... ICOTF), today reported financial results for the six ... otherwise, are expressed in Canadian dollars and presented ... Second Quarter 2014 Highlights , Announced ... acuity (VA) primary endpoint for subjects enrolled in ...
(Date:8/29/2014)... (PRWEB) August 29, 2014 A major ... the biotech start-up dense realm of Boston-Cambridge, is gaining ... able investors. James Sherley, the Director of Boston’s Adult ... the local and national visibility of his company an ... 2013. , In addition to a social media marketing ...
(Date:8/28/2014)... Best Sanitizers, Inc., the first company to ... asks food processors and food handling professionals to prepare ... currently using to Best Sanitizers’ Alpet® E3 Plus ... fighting cross-contamination and the spread of pathogens in the ... key criteria that make a hand sanitizer most effective, ...
Breaking Biology Technology:Breakthrough in light sources for new quantum technology 2iCo Therapeutics Announces Second Quarter 2014 Financial Results 2iCo Therapeutics Announces Second Quarter 2014 Financial Results 3iCo Therapeutics Announces Second Quarter 2014 Financial Results 4The Adult Stem Cell Technology Center, LLC Participates in Multiple Stem Cell and Regenerative Medicine Conferences Before Year End 2The Adult Stem Cell Technology Center, LLC Participates in Multiple Stem Cell and Regenerative Medicine Conferences Before Year End 3The Adult Stem Cell Technology Center, LLC Participates in Multiple Stem Cell and Regenerative Medicine Conferences Before Year End 4Food Processors and Food Handlers are Encouraged to Prepare for Fall Harvest by Evaluating Their Current Hand Sanitizer Using Nine Key Criteria 2Food Processors and Food Handlers are Encouraged to Prepare for Fall Harvest by Evaluating Their Current Hand Sanitizer Using Nine Key Criteria 3
... ATLANTA, May 1 CryoLife, Inc., (NYSE: ... company, announced today,that Harvey Morgan has been elected ... Morgan is a Managing Director at Bentley,Associates L.P., ... more than 35 years of investment banking experience ...
... accelerating market penetration and revenue growth, SCOTTSDALE, ... technology company that markets the Provant(R) Wound Therapy,System, ... as Vice,President of Marketing. Most recently Mr. Robey ... Inc (KCI) for the V.A.C.(R) Therapy,brand, during the ...
... SEATTLE, May 1 Therapies under development to ... growth factor,(IGF-1) to activate its target receptor could ... gene -- p53 -- is already,compromised, according to ... Center., IGF-1 is a polypeptide hormone that ...
Cached Biology Technology:Harvey Morgan Joins CryoLife Board of Directors 2Regenesis Biomedical Advances Corporate Strategy by Appointing Vice President of Marketing 2New Study Raises Questions About Prostate Cancer Therapies Targeting Insulin-Like Growth Factor Receptor 2New Study Raises Questions About Prostate Cancer Therapies Targeting Insulin-Like Growth Factor Receptor 3
(Date:8/29/2014)... has been known about what genetic changes transform wild ... one of whom is a University of Montana assistant ... controlling the development of the brain and the nervous ... was published Aug. 28 in Science and ... at http://www.sciencemag.org/ ., The domestication of animals and ...
(Date:8/29/2014)... in German . ... natural nitrogen cycle on Earth and in biological wastewater ... to depend on nitrite as their source of energy. ... a microbiologist at the University of Vienna, has now ... alternative source of energy. The oxidation of hydrogen with ...
(Date:8/29/2014)... Bend them, stretch them, twist them, fold them: modern ... extraordinary technological potential, whether as artificial skin or electronic ... use remains a challenge but a new way of ... could be a game-changer. , Previous success in ... on the use of precious gold and silver nanowires. ...
Breaking Biology News(10 mins):New research reveals how wild rabbits were genetically transformed into tame rabbits 2New research reveals how wild rabbits were genetically transformed into tame rabbits 3Hydrogen powers important nitrogen-transforming bacteria 2Hydrogen powers important nitrogen-transforming bacteria 3Copper shines as flexible conductor 2
... to treat bacterial infections causes a continual and vicious ... and spread of resistant strains, forcing the use of ... what if it doesn,t have to be that way? ... Biochemistry and Molecular Biology,s annual meeting, titled "Driving backwards ...
... We all know that eating a calcium-rich diet is ... concept is clearly on display in any elementary school ... with celebrity icons encouraging children to make sure they ... urging school-aged children to pay attention to their dairy ...
... genes out of action allows researchers to learn what genes ... Utah biologists pioneered the field. Mario Capecchi won a Nobel ... to cripple fruit fly genes. Now, biologist Erik Jorgensen and ... nematode worms. "We developed a method that allows us ...
Cached Biology News:Putting bacterial antibiotic resistance into reverse 2Study suggests a much earlier onset for bone problems 2Study suggests a much earlier onset for bone problems 3Worm genes KO'd 2Worm genes KO'd 3Worm genes KO'd 4Worm genes KO'd 5
Mouse polyclonal antibody raised against a partial recombinant MHC2TA. NCBI Entrez Gene ID = 4261...
Mouse monoclonal antibody raised against a partial recombinant JRKL. NCBI Entrez Gene ID = JRKL...
... Polymorphic DNA Technologies also offers a DNA ... of templates including plasmids, PCR products, BACs, ... customer-provided templates such as purified plasmids or ... liquid handling robotics optimized for automated reaction ...
... a premium quality recombinant form of Thermus ... suitable for a wide range of PCR ... reproducible performance, each preparation is extensively tested ... NovaTaq DNA Polymerase possesses an integral 5′→3′ ...
Biology Products: